258 related articles for article (PubMed ID: 35734618)
1. Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms.
Que QY; Zhang LC; Bao JQ; Ling SB; Xu X
World J Gastrointest Surg; 2022 May; 14(5):397-408. PubMed ID: 35734618
[TBL] [Abstract][Full Text] [Related]
2. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study.
Pu N; Habib JR; Bejjani M; Yin H; Nagai M; Chen J; Kinny-Köster B; Chen Q; Zhang J; Yu J; Wu W; Lou W
Ann Transl Med; 2021 Feb; 9(4):329. PubMed ID: 33708956
[TBL] [Abstract][Full Text] [Related]
3. Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.
Cui Y; Li X; Gao S; Li Z; Li Y; Lu M; Sun Y
Chin J Cancer Res; 2018 Feb; 30(1):31-39. PubMed ID: 29545717
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
[TBL] [Abstract][Full Text] [Related]
5. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
[TBL] [Abstract][Full Text] [Related]
6. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.
Takayanagi D; Cho H; Machida E; Kawamura A; Takashima A; Wada S; Tsunoda T; Kohno T; Shiraishi K
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267427
[TBL] [Abstract][Full Text] [Related]
7. How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.
Fermi F; Andreasi V; Muffatti F; Crippa S; Tamburrino D; Partelli S; Falconi M
Curr Oncol Rep; 2022 Feb; 24(2):227-239. PubMed ID: 35076884
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs).
Mohamed A; Asa SL; McCormick T; Al-Shakhshir H; Dasari A; Mauricio R; Salem I; Ocuin LM; Bajor D; Lee RT; Selfridge JE; Kardan A; Lee Z; Avril N; Kopp S; Winter JM; Hardacre JM; Ammori JB; Ghannoum MA
Curr Issues Mol Biol; 2022 Apr; 44(5):2015-2028. PubMed ID: 35678665
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
11. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
13. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Kaliszewski K; Ludwig M; Greniuk M; Mikuła A; Zagórski K; Rudnicki J
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454934
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
16. Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism.
Santos AP; Vinagre J; Soares P; Claro I; Sanches AC; Gomes L; Fernandes I; Catarino AL; Preto J; Pereira BD; Marques AP; Rodrigues F; Amaral C; Rocha G; Mellidez JC; Simões H; Lopes JM; Bugalho MJ;
Int J Endocrinol; 2019; 2019():4518742. PubMed ID: 31467527
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot.
Fernandez CJ; Agarwal M; Pottakkat B; Haroon NN; George AS; Pappachan JM
World J Gastrointest Surg; 2021 Mar; 13(3):231-255. PubMed ID: 33796213
[TBL] [Abstract][Full Text] [Related]
18. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
[TBL] [Abstract][Full Text] [Related]
20. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?
Cavalcoli F; Rausa E; Conte D; Nicolini AF; Massironi S
World J Gastroenterol; 2017 Apr; 23(15):2640-2650. PubMed ID: 28487601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
